Eciskafusp Alfa

N/A

Report date: 2025/04/25 15:10:48

Base Information

Drug NameEciskafusp Alfa
Drug Alias NameRO-7284755RG-6279PD1-IL2v
ClassificationBiologics > Protein drugs > Recombinant protein > Fusion protein
Mechanisms of ActionAnti-PD-1Interleukin-2 receptor agonists
TargetsProgrammed cell death protein 1Interleukin-2 receptor
Therapy Area/IndicationsSolid tumoursUrinary Bladder Neoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryBelgiumPolandNetherlands +[8] 
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesF. Hoffmann-La Roche Ag
China Registration ClassN/A

Develop Information

Active CompaniesF. Hoffmann-La Roche Ltd
Inactive CompaniesN/A
Active IndicationsSolid tumours
Inactive IndicationsUrinary Bladder Neoplasms

Other Information

ATC CodeN/A
Related LinksN/A